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Aims TheGenousTM Bio-engineeredRTM stent (GS)aimstopromotevascularhealingbycaptureofcirculatoryendothelialpro-
genitorcells (EPCs) to thesurfaceofthe stentstruts,resulting in accelerated re-endothelialization. Here, we assessed the
function of the GS in comparison to bare-metal stent (BMS), when exposed to the human and animal circulation.
Methods
and results
First, 15 patients undergoing coronary angiography received an extracorporeal femoral arteriovenous (AV) shunt
containing BMS and GS. Macroscopical mural thrombi were observed in BMS, whereas GS remained visibly clean.
Confocal and scanning electron microscopic (SEM) analysis of GS showed an increase in strut coverage. Quantitative
polymerase chain reaction (qPCR) analysis of captured cells on the GS demonstrated increased expression of endo-
thelial markers KDR/VEGFR2 and E-selectin, and a decrease in pro-thrombogenic markers tissue factor pathway
inhibitor and plasminogen activator inhibitor-1 compared with BMS. Secondly, a similar primate AV shunt model
was used to validate these ﬁndings and occlusion of BMS was observed, while GS remained patent, as demonstrated
by live imaging of indium-labelled platelets. Thirdly, in an in vitro cell-capture assay, GS struts showed increased cover-
age by EPCs, whereas monocyte coverage remained similar to BMS. Finally, the assessment of re-endothelialization
was studied in a rabbit denudation model. Twenty animals received BMS and GS in the aorta and iliac arteries for
7 days. Scanning electron microscopic analysis showed a trend towards increased strut coverage, conﬁrmed by
qPCR analysis revealing increased levels of endothelial markers (Tie2, CD34, PCD31, and P-selectin) in GS.
Conclusion In this proof-of-concept study, we have demonstrated that the bio-engineered EPC-capture stent, GenousTM RTM
stent, is effective in EPC capture, resulting in accelerated re-endothelialization and reduced thrombogenicity.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Vascular homeostasis is maintained by the endothelial cell (EC)
layer that is involved in the regulation of platelet adhesion,
vasomotor function, and cell cycle quiescence of the cellular con-
stituents of the vascular wall.
1 Bone marrow-derived circulating
endothelial progenitor cells (EPCs) aid in the regeneration of
damaged and dysfunctional endothelium and therefore play a
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2–4 Recruitment of
EPCs to the site of vascular injury has been proposed to
promote vascular healing and has been shown to inhibit neointimal
proliferation and restenosis associated with percutaneous coron-
ary intervention (PCI).
5 The GenousTM Bio-engineered RTM stent
(GS) (OrbusNeich Medical BV, Hoevelaken, The Netherlands)
has been developed to enhance the capture of circulating EPCs
to the stent surface using an immobilized antihuman-CD34 mono-
clonal antibody. CD34 was previously shown to be expressed in
circulating haematopoietic cells in humans.
4,6 The sequestered
EPCs are thought to enhance endothelial healing and thus
protect the stented vascular segment against acute thrombosis
with minimized neointimal hyperplasia.
The safety, feasibility, and efﬁcacy of the GS in human coronary
artery disease (CAD) have been the subject of multiple clinical
studies.
7–11 Although the long-term effect of the GS on clinical
outcome has been investigated, the efﬁcacy of the bio-engineered
stent to promote initial endothelial recovery has never been
shown in humans before. Here, we studied early cellular inter-
actions of the GS within the circulation of CAD patients.
In the ﬁrst part of the study, a temporary ex vivo arteriovenous
(AV) shunt was established by cannulation of the femoral artery
and vein and connection of the two via a synthetic tube comprising
the bare-metal stent (BMS) and the GS. The stents were exposed
to the human circulation under continuous ﬂow. Endothelial pro-
genitor cell capture and subsequent EPC differentiation were ana-
lysed using conventional ultrastructural analysis as well as by
quantifying surrogate endothelial markers on the captured stent
by quantitative polymerase chain reaction (qPCR) analysis. In the
second part of the study, the validation of accelerated endothelia-
lization was further conducted in a well-established primate model
for stent-related thrombogenicity. In the third part, CD34+ cell-
capture speciﬁcity was evaluated in an in vitro capture model. In
the ﬁnal part of the study, long-term effects of the GS on the
vascular endothelium were evaluated in a rabbit model of arterial
balloon injury and vascular repair.
Methods
Study population
The study was performed in 15 patients undergoing elective heart
catheterization, followed in 11 cases by PCI. Informed written
consent was obtained prior to the procedure for all patients. The
study was reviewed and approved by the institution’s ethics review
committee. The baseline characteristics of included patients are
shown in Table 1.
Ex vivo human arteriovenous shunt
The GS (OrbusNeich) is coated with an immobilized murine mono-
clonal antibodies directed against human CD34, a known antigen
expressed on EPCs. It is designed to capture circulating EPCs to
promote vascular healing. Patients received an extracorporeal AV
shunt containing two GSs and two BMSs (non-coated, stainless steel
R-stent). From each patient, one randomized stent of each group
(BMS or GS) was used for qPCR analysis and one was used for scan-
ning electron microscopic (SEM) assessment. The positions of the
stents in the shunt were equally alternated in the studied patient
group to prevent location bias (see Supplementary material online,
Figure S2). For a detailed description of the protocol, see Supplemen-
tary material online.
Rabbit model of arterial balloon injury
The early effects of Genous in accelerated re-endothelialization were
further assessed in a rabbit endothelial denudation model.
12 Stents
were implanted in 20 New Zealand white adult male rabbits. One
BMS and one GS were implanted per rabbit in the aorta (for qPCR
analysis, n ¼ 11) and iliac artery (for SEM analysis, n ¼ 9). For the
aorta, the stents were alternated in order. All stents were deployed
at nominal pressure (9 atm) for 30 s. Angiography was performed to
conﬁrm appropriate stent placement and vessel diameter post-
deployment. At 7 days post-stenting, follow-up angiography was
performed. To obtain stent samples for SEM analysis, the rabbits
were perfusion ﬁxed in 10% formalin and the stented arteries were
harvested. For qPCR analysis, the vessels were isolated without in
situ ﬁxation, and the stents were removed and incubated in RNA
isolation buffer (RLT buffer, Qiagen, The Netherlands) and stored at
2808C until qPCR analysis.
Statistical analysis
Statistical analysis was performed using Graphpad Prism software
(version 4.0b). All data are expressed as means+SEM. Comparisons
between the patients groups are performed using a paired or a non-
paired two-sided Student’s t-test or a linear regression analysis when
................................................................................
................................................................................
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Table 1 Characteristics of the patients
Patients characteristics n Per cent
Male 10 66.67
Age 69.4+7
PCI 11 73.33
Oypertension 8 53.33
Diabetes mellitus 0 0
Dyslipidaemia 5 33.33
Smoking 6 40
Clinical pattern
Stable angina pectoris 10 66.67
Unstable angina pectoris 4 26.67
Syncope 1 6.667
Peripheral vascular disease 3 20
Stroke 2 13.33
Heart failure 3 20
Previous myocardial infarction 4 26.67
Previous PCI 7 46.67
Previous CABG 2 13.33
Use of:
Statin 14 93.33
Aspirin 13 86.67
Clopidogrel 13 86.67
Warfarin 2 13.33
b-Blockers 3 20
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.
Capture of circulatory EPCs 121appropriate after normal distribution was validated for the data set. A
P-value of ,0.05 is considered statistically signiﬁcant.
For the SEM protocol, mRNA processing, baboon AV shunt study,
and in vitro CD34+-capture stent validation, see Supplementary
material online, Material and methods.
Results
Part 1: Human arteriovenous shunt study
reveals evidence of accelerated capture
of endothelial progenitor cells and
protection against in-stent thrombosis
and inﬂammation in Genous vs.
bare-metal stent
The GS has been tested extensively in animal models,
13 but direct
evidence of the in vivo EPC-capture capability of this stent in the
human circulation has not been presented. In the ﬁrst part of
the study, we investigated the acute effect of the GS in patients
undergoing coronary angiography. In addition, assessment of the
GS in a CAD patient setting provides relevant evaluation of bioac-
tivity of the CD34-capture antibody that was raised speciﬁcally
against human CD34 antigen (Supplementary material online,
Figure S1). In this study, the EPC-capture capacity of the GS was
compared with that of uncoated, stainless steel R-stents (BMSs).
The GS and the BMS that were tested in the human AV shunt
model were exposed to the circulation for up to 120 min. Stents
selected for SEM analysis revealed marked increase in strut cell cov-
erage in the GS when compared with BMS (Figure 1A and C: BMS,
Figure 1B and D: GS). Average stent-strut coverage was visually
ratedbyablinded(core-lab)technicianona0–3scale(correspond-
ing to 0–25, 25–50, 50–75, and 75–100% stent coverage). Cell
deposition on the struts was enhanced by 32.5% (P ¼ 0.006,
n ¼ 9) in GSs when compared with BMS in paired analysis
(Figure1E).High-resolutionassessmentoftheSEMdatarevealedcel-
lulardepositspresentonbothstentsthatcouldbedistinguishedinto
a population of cells with a rounded and ﬂattened morphology, cells
with a more monocyte-like appearance, and blood platelets. To
furtherelucidatetheidentityofthismixedpopulation,weperformed
byqPCRthecellularsubstrate.MacroscopicalcomparisonofGSand
BMS also revealed the substantial presence of mural thrombi in the
two BMSs, whereas all of the GSs remained free of thrombogenic
material (Figure 1F and G). This observation led us to further
examine markers of thrombogenicity and coagulation by qPCR.
For qPCR analysis, cells were directly lysed from the stents and
subsequently analysed by qPCR using the housekeeping genes
GAPDH and b-actin to normalize for cell content and quality of
total RNA. Quantitative polymerase chain reaction analysis of
the attached cells showed no signiﬁcant difference in CD34
expression between the GS and BMS groups (data not shown).
However, evaluation of endothelial markers revealed a marked
increase in KDR/VEGFR2 (P , 0.001) and E-selectin RNA
expression (P , 0.045) with the GSs, when compared with BMS
(Figure 2A). However, the expression of another endothelial
speciﬁc marker Plvap (Figure 2A) showed no signiﬁcant increase
in the GS group (P ¼ 0.21).
An equivalent CD34 transcript content, with enhanced
expression of endothelial markers would suggest accelerated
ongoing differentiation into the endothelial lineage concomitant
with down-regulation of CD34 expression.
Quantitative polymerase chain reaction evaluation of markers of
thrombosis and coagulation (Figure 2B) revealed a signiﬁcant
decrease in expression of tissue factor pathway inhibitor (TFPI)
and plasminogen activator inhibitor-1 (PAI-1) in GS compared
with BMS (P ¼ 0.04 and 0.02, for TFPI and TF, respectively),
suggestive of a less pro-thrombotic state of the cells attached to
the GS and thus a reduced risk for stent thrombogenicity.
To assess the potency of the GS to protect the vascular wall
against inﬂammation, inﬂammatory markers were also included in
the study. CD16 is an established neutrophil expression marker.
Cells sequestered to the GS presented lower expression levels
of CD16 over time (R
2 ¼ 0.7641, P , 0.002), whereas the
BMS showed persistent CD16+ expression in attached cells
(R
2 ¼ 0.0013, P , 0.932), suggesting that adhesion of CD16+
inﬂammatory cells was prevented by accelerated capture of
CD34+ endothelial progenitors and subsequent coverage of the
stent struts (Figure 2C). Moreover, the inﬂammatory markers for
immune cell subpopulations were not signiﬁcantly different
between the stents, including CD68, CD14, monocyte chemoat-
tractant protein-1, CXCR-1, and VCAM1 (data not shown).
Combined, these qPCR analyses corroborate and extend the
ultrastructural analysis by SEM and conﬁrm enhanced attachment
of circulating EPCs to the GS surface. In addition, these data
suggest that the attached cells could undergo rapid endothelial
commitment and differentiation (loss of CD34, increased
expression of KDR1/E-selectin), with reduced thrombogenicity
and inﬂammatory response of the injured vascular wall.
Part 2: Genous inhibits in-stent
thrombosis in a baboon arteriovenous
shunt model
Based on the differences in thrombogenicity by qPCR and the lack
of mural thrombi in the GS as observed in the clinical study, we
further assessed thrombogenicity of the GS in an established
primate model using a similar AV shunt setup with exclusion of
anti-platelet treatment in the protocol. Live deposition of platelets
and ﬁbrinogen was studied in the AV shunt setup by measuring the
accumulation of indium-labelled platelets with a gamma camera for
up to 2 h. In line with the human data, the GS had a lower throm-
bogenic potential than BMS in the baboon shunt model. Within
65 min after initiation of the experiment, the BMS were occluded
with a ﬂow-limiting thrombus, whereas the GSs remained patent
for at least 2 h (Figure 3A). Further SEM analysis revealed increased
platelet deposition and in-stent thrombus formation in BMS vs. GS
(Figure 3B). Platelet deposition was signiﬁcantly higher in BMS com-
pared with GS after ﬂow exposure as quantiﬁed by gamma camera
(1.13+0.57 × 10
9 when compared with 0.50+0.22 × 10
9 plate-
lets, in BMS vs. Genous, respectively, P ¼ 0.04; Figure 3C). Although
ﬁbrinogen accumulation seemed less prominent on the GS when
compared with BMS, no statistical difference was found between
the groups. The values were 0.05+0.02 and 0.18+0.10 mg/
stent for the GS and BMS, respectively.
K. Larsen et al. 122Figure 1 Scanning electron microscopic analysis of the endothelial progenitor cell capturing stent and bare-metal stent in the human arter-
iovenous shunt model revealed a marked increase in cell strut coverage compared with bare-metal stent. Scanning electron microscopic inspec-
tion of the study stents showed less strut coverage and the presence of thrombus-like structures on bare-metal stent (A) when compared with
Genous stent (B). High-magniﬁcation scanning electron microscope revealed more adhesion of cells with a ﬂattened polygonal morphology on
the struts of the Genous stent (D) vs. bare-metal stent (C). Average stent-strut coverage was visually rated by blinded (core lab) technicians
(CV-Path Institute, USA) on a 0–3 virtual scale (corresponding to 0–25, 25–50, 50–75, and 75–100% stent coverage). Bar graph indicates the
level of strut coverage as assessed by scanning electron microscope in the two stent study groups. *P , 0.05, n ¼ 9( E). Macroscopic appear-
ance of bare-metal stent (F) and Genous (G) stents in the human ex vivo shunt model shows mural thrombi in the bare-metal stent, whereas the
Genous stent remained free of thrombogenic material.
Capture of circulatory EPCs 123Figure 2 Quantitative polymerase chain reaction evaluation of cellular markers in cell lysates of captured cells in the human arteriovenous
shunt stent model. Paired comparison of the expression levels of the individual genes revealed a marked increase in endothelial markers, includ-
ing KDR/VEGFR2 (P , 0.001) and E-selectin (P , 0.045) mRNA expression in the stents compared with bare-metal stent (A). Expression of
another endothelial speciﬁc marker PLVAP (A) showed no signiﬁcant increased expression in the stent (P ¼ 0.21). Quantitative polymerase
chain reaction analysis of markers of thrombosis, coagulation, and inﬂammation. Paired comparison of the expression levels of the individual
genes revealed a marked decrease in tissue factor pathway inhibitor and plasminogen activator inhibitor-1 in the Genous compared with
the bare-metal stent (B)( P ¼ 0.04 and 0.02). Quantitative polymerase chain reaction showed a signiﬁcant decrease in CD16 marker expression
in the cells captured by the Genous stent over time, whereas the CD16 mRNA levels on bare-metal stent were maintained (C)( * P , 0.05).
K. Larsen et al. 124Figure 3 Live imaging of arteriovenous shunt setup using a gamma camera to measure deposition of indium-labelled platelets on the study
stents (A). Line graph shows a typical example of accumulating platelet signal over time. Low-magniﬁcation scanning electron microscope images
of the bare-metal stent and the endothelial progenitor cell-capture stent in the baboon arteriovenous shunt model revealed a decrease in mural
thrombus in the Genous vs. bare-metal stent (B). Bar graph showing the quantiﬁed number of platelets accumulated on the bare-metal stent and
Genous stent after 2 h of ﬂow exposure (C). Data were acquired from the live imaging of arteriovenous shunt setup, *P , 0.05, n ¼ 3. In vitro
assay to test the CD34+ cell-capture speciﬁcity of the Genous stent. Genous and BM stents were deployed in silicon tubing and were exposed
to a cell mixture of PKH26 red ﬂuorescent-labelled human monocytes (1 × 10
6 cells/mL) and PKH2 green ﬂuorescent-labelled human CD34+
cells (2 × 10
5 cells/mL), under a constant rotation speed of 0.3 RPM for 2 h. Micrographs show confocal images of strut coverage of bare-metal
stent and Genous stent (D). Bar graph shows the quantiﬁed number of CD34+ cells and monocytes per cm
2 strut area. *P , 0.05, n ¼ 3( E).
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demonstrates speciﬁc adhesion of human
peripheral blood-derived CD341 cells
on Genous CD34-capture stents
To examine whether the CD34 antibody on the GS is also able to
bind the more abundant circulatory inﬂammatory cells such as
monocytes, an in vitro assay was performed to test the CD34+
cell-capture speciﬁcity of the GS. Genous stent and BMS were
deployed in silicon tubing and were exposed to a cell mixture of
PKH26 red ﬂuorescent-labelled human monocytes (1 × 10
6 cells/
mL) and PKH2 green ﬂuorescent-labelled human CD34+ cells
(2 × 10
5 cells/mL), under a constant rotation speed of 0.3 RPM
for 2 h. Confocal assessment of the stent struts showed a
greater number of CD34+ cells to adhere to the GS-strut
surface when compared with BMS; cell density for CD34+ cells
was 500+158 cells/cm
2 strut area on the GS vs. 17+8 cells/
cm
2 on the BMS (P ¼ 0.0009; Figure 3D and E). In contrast, mono-
cyte adherence was not signiﬁcantly different between the two
stent types, although a trend was observed (79+44 cells/cm
2
when compared with 58+39 cells/cm
2, GS vs. BMS, respectively,
P ¼ 0.07; Figure 3D and E).
Therefore, the speciﬁcity of the GS to capture CD34+ cells was
signiﬁcantly higher when compared with BMS, as 86% of the
attached cells were CD34+ when compared with only 26% on
the BMS.
Part 4: Genous stent promotes
re-endothelialization at 7 days in rabbit
endothelial denudation model
Twenty New Zealand white rabbits received stent placement after
endothelial denudation in the aorta, n ¼ 11, and iliac artery, n ¼ 9
(left GS and right BMS). From 11 animals, the aortic stents were
harvested after 7 days and the cell lysates were evaluated for EC
markers. Quantitative polymerase chain reaction analysis showed
signiﬁcant increased levels of endothelial markers in the GS vs.
BMS treated artery including Tie2 (P ¼ 0.02) and P-selectin
(P ¼ 0.05), whereas CD34 (P ¼ 0.08) and CD31 (P ¼ 0.07)
levels showed positive trends, indicating that the GS promoted
long-term endothelialization (Figure 4A).
These data support our ﬁnding of the AV shunt study in CAD
patients where we propose earlier endothelialization in GS
compare with BMS. In line with these ﬁndings, SEM analysis of
nine rabbits that received the Genous (left) or BM (right) in bilat-
eral denudated iliac arteries showed a trend of increased strut cov-
erage at 7 days post-implantation (Figure 4B–D). Together, these
data indicate that the GS efﬁciently promotes re-endothelialization
in a denudated vessel wall environment as shortly as 7 days after
placement.
Discussion
In this study, we have demonstrated for the ﬁrst time that
bio-engineered endothelial progenitor (EPC)-capture stent tech-
nology is successful in EPC capture in the human circulation,
resulting in effective re-endothelialization and decreased
thrombogenicity.
Endothelialization is a critical step in the initiation of vascular
repair following stent implantation. Re-endothelialization of the
damaged area involves activation and migration of resident EC
adjacent to the stent area or by recruitment of blood-derived
EPC. Early presence of a functional endothelial lining after vascular
injury could improves the process of vascular healing and reduces
the risk of restenosis an acute thrombosis.
The stent struts of the bio-engineered R stent (GENOUS
w)
incorporate an immuno-afﬁnity surface, consisting of covalently
bound monoclonal antibodies directed against the human CD34
antigen, a cell surface marker found on circulating EPC. Endothelial
progenitor cell capture by the GENOUS
w R stent is shown sche-
matically in Figure 1 of Supplementary material online, Figure S1.
The efﬁcacy of EPC capture and re-endothelialization of the GS
has been extensively evaluated in porcine models
13 relying on
the cross-reactivity of the monoclonal CD34 antibody against
porcine CD34. Although these studies gave a clear indication of
stent performance, optimal capture efﬁcacy by the human
CD34-directed antibody can only be truly tested under circum-
stances when the stent is exposed to the human circulation.
Here, the performance of the BMS and the bio-engineered GS
was studied in an ex vivo AV shunt construction in which stents
were exposed to the human circulation for up to 2 h. The data
of this study provide for the ﬁrst time direct evidence of the
capture efﬁciency of a bio-engineered-capture stent in the
human circulation.
Previous studies have shown that at least in the porcine models,
the efﬁcacy of EPC-capture stent coverage was similar to that of
BMS, with a optimal endothelial coverage of total stented area of
99% in both groups.
13 However, it has to be taken into account
that the lack of difference in response could be due to a low cross-
reactivity of the human CD34 antibody on the GS against porcine
CD34 antigen, resulting in a suboptimal EPC capture. The ex vivo
AV shunt data in the patients and primates in the current study
showed that the GS was capable of rapid capture of circulating
progenitor cells within the ﬁrst hours of exposure. Scanning elec-
tron microscopic and qPCR analysis have subsequently validated
the endothelial phenotype of the adherent population. Taken
together, our data indicate that the EPC-capture stent is capable
of accelerating the re-endothelialization process in exposure to
the human circulation and therefore aid the vascular healing after
vascular injury when compared with the BMS.
The combination of the EPC-capture and drug-elution technol-
ogy has shown thus far to be a promising strategy in the preclinical
setting.
13 In contrast to that type of study, which focuses on late
stent outcome, this study was predominantly designed to
provide ﬁrst-time proof of efﬁcient EPC capture in human patients.
Therefore, we have chosen to focus on capture efﬁciency alone
and compare the GS with the BMS. Although we have provided
adequate proof for this cell-capture technology, drug elution may
compromise the cell-capture efﬁciency and should be investigated
for each of the new generation of combo-devices that are
currently being developed.
A second important ﬁnding reported in this study is the effect of
the GS on thrombogenesis. The rapid coverage of the GS by a
K. Larsen et al. 126protective endothelial lining was hypothesized to protect the
stented area from thombogenesis and inﬂammation, thereby pro-
moting a more efﬁcient healing of the vascular wall. Indeed, macro-
scopic comparison of the GS and BMS revealed the clear presence
of mural thrombi in the BMS of one of the patients, whereas all the
EPC-capture stent remained free of visible thrombi. It should be
mentioned that this particular patient only received ASA (no clopi-
dogrel therapy) before PCI. Although the patient’s blood was
Figure 4 Quantitative polymerase chain reaction analysis of the study stents of 11 New Zealand white rabbits was performed to evaluate
capture of cells and subsequent expression of endothelial cell markers. Paired quantitative polymerase chain reaction analysis showed increased
levels of endothelial markers by the cells captured on the Genous stent vs. bare-metal stent treated arteries, including Tie2 (P ¼ 0.02), CD34
(P ¼ 0.07), CD31 (P ¼ 0.08), and P-selectin (P ¼ 0.05). *P , 0.05,
fP , 0.01, n ¼ 11 (A). Scanning electron microscopic analysis of the stents
implanted iliac vessels of 9 New Zealand white rabbits: Low (B)- and high (C)-magniﬁcation assessment revealed improved cell coverage
between and above struts in the Genous stent vs. bare-metal stent. Bar graph shows the level of strut coverage as analysed by scanning electron
microscope in the two stent groups.
fP , 0.01, n ¼ 9( D).
Capture of circulatory EPCs 127exposed to both GS and BMS and the GSs showed no signs of
thrombi, the striking difference in thombogenic response between
the two stent types could be related to the absence of anti-platelet
aggregationsurfacemarkers.Tofurtherelucidatethis,biomarkersof
coagulation and thrombosis were further examined in the human
shunt material. We observed signiﬁcant down-regulation in PAI
and TFPI expression in the lysates of EPC-capture stent when com-
pared with BMS, pointing to platelet aggregation on the stent
struts.
14 Similarly, TFPI mRNA enrichment in the attached cells indi-
cates in the BMS a rich platelet environment promoted by recruited
inﬂammatory cells.
15,16 Summarized, these data point to active EPC
recruitment as playing a putative role in vascular protection against
stent thrombosis. These ﬁndings were further validated in the
baboon shunt experiments. For an extended discussion on this
subject, see Supplementary material online.
The early EC lining on the stent could protect against active
accumulation of inﬂammatory cells involved in the innate
immune response. However, in line with the in vitro ﬁndings,
there was no difference in other inﬂammatory markers or innate
immunity markers such as CD68, CD14, MCP1, and CXCR-1.
This could be due to the short exposure time, but, more impor-
tantly, paracrine stimulation by the injured vessel wall is lacking
in the human AV shunt setup. In the absence of cytokine and che-
mokine release to trigger inﬂammatory cell activation, the protec-
tive effect of the stent re-endothelializing by circulating EPCs
on the inﬂammatory response may only be limited. Previously,
Granada et al. performed a comparison study of stents (combining
CD34 capture with the sirolimus-eluting strategy) with conven-
tional drug-eluting stents including Xience and Cypher in a
porcine experimental model. It was demonstrated that the EPC-
capture technology further diminished overall intimal inﬂammation
and giant cell accumulation after 28 days of implantation in the
coronary arteries when compared with the Cypher and Xience
stents.
13 This was associated with a decrease in neointimal
growth. This suggests that active re-endothelialization of
drug-eluting stents could indeed protect the injured vascular wall
from further inﬂammatory activation, thereby protecting the
stented area from further platelet adhesion and restenosis.
13
Based on these ﬁndings, the GS should provide vascular protection
against thrombosis in the patients in short- and long-term
follow-up. Recently, supporting data were presented by the
e-HEALING (Healthy, Endothelial Accelerated Lining inhibits
Neointimal Growth) multicentre registry in which the long-term
effect of the GS was followed in 5000 patients. Indeed, low
levels of in-stent thrombosis and repeat revascularization of 1.1
and 5.7%, respectively, were observed at 12-month post-
intervention.
17 New clinical trails are currently under evaluation
in which the CD34-capture technology will be combined with sir-
olimus elution to assess novel combination strategies (REMEDEE:
NCT00967902).
In conclusion, we showed in an AV shunt construction in human
CAD patients and baboons that the CD34+ EPC recruitment pro-
motes re-endothelialization and inhibited platelet adhesion. This
speciﬁc aspect of the biological behaviour of the GS is especially
promising as it could, combined with a drug-eluting strategy,
13
yield safe and efﬁcient therapy against restenosis, while diminishing
the need for dual anti-platelet therapy after stent implantation.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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